Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2018
Summary
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) pipeline Target consti
- Introduction
- Global Markets Direct Report Coverage
- Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Overview
- Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Companies Involved in Therapeutics Development
- Amgen Inc
- Arena Pharmaceuticals Inc
- CymaBay Therapeutics Inc
- Dong-A Socio Holdings Co Ltd
- Hyundai Pharmaceutical Co Ltd
- Japan Tobacco Inc
- Kowa Co Ltd
- Merck & Co Inc
- Novartis AG
- Taisho Pharmaceutical Holdings Co Ltd
- Yuhan Corp
- Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Drug Profiles
- APD-597 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- DA-1241 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- HOB-047 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- MBX-2982 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SCO-094 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Agonize GPR119 for Type 2 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Agonize GPR119 for Type 2 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Agonize GPR119 Receptor for Unspecified Indication - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Agonize GRP119 for Type 2 Diabetes and Obesity - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Agonize GPR119 for Type 2 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Agonize GPR119 for Type 2 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Agonize GPR119 for Type 2 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- YH-18420 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Dormant Products
- Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Discontinued Products
- Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Product Development Milestones
- Featured News & Press Releases
- Nov 04, 2010: Arena Pharmaceuticals Provides Update On GPR119 Portfolio For Type 2 Diabetes
- Nov 05, 2009: Metabolex Closes $8.6 Million Financing Round
- Dec 15, 2008: Arena Pharmaceuticals Announces Initiation Of Phase I Clinical Trial Of Type 2 Diabetes Drug Candidate In Partnership With Ortho-McNeil-Janssen Pharmaceuticals
- Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982
- Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development by Stage of Development, H2 2018
- Number of Products under Development by Therapy Areas, H2 2018
- Number of Products under Development by Indication, H2 2018
- Number of Products under Development by Companies, H2 2018
- Products under Development by Companies, H2 2018
- Number of Products under Investigation by Universities/Institutes, H2 2018
- Products under Investigation by Universities/Institutes, H2 2018
- Number of Products by Stage and Mechanism of Actions, H2 2018
- Number of Products by Stage and Route of Administration, H2 2018
- Number of Products by Stage and Molecule Type, H2 2018
- Pipeline by Amgen Inc, H2 2018
- Pipeline by Arena Pharmaceuticals Inc, H2 2018
- Pipeline by CymaBay Therapeutics Inc, H2 2018
- Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018
- Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2018
- Pipeline by Japan Tobacco Inc, H2 2018
- Pipeline by Kowa Co Ltd, H2 2018
- Pipeline by Merck & Co Inc, H2 2018
- Pipeline by Novartis AG, H2 2018
- Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2018
- Pipeline by Yuhan Corp, H2 2018
- Dormant Products, H2 2018
- Dormant Products, H2 2018 (Contd..1), H2 2018
- Discontinued Products, H2 2018
- List of Figures
- Number of Products under Development by Stage of Development, H2 2018
- Number of Products under Development by Therapy Areas, H2 2018
- Number of Products under Development by Top 10 Indications, H2 2018
- Number of Products by Stage and Mechanism of Actions, H2 2018
- Number of Products by Routes of Administration, H2 2018
- Number of Products by Stage and Routes of Administration, H2 2018
- Number of Products by Molecule Types, H2 2018
- Number of Products by Stage and Molecule Types, H2 2018
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook